HBM (HKG:2142) subsidiary Nona Biosciences and Candid Therapeutics signed a research collaboration and license agreement for next-generation T-cell engagers, according to a Monday filing with the Hong Kong Exchange.

As part of the deal, Nona will be able to receive $320 million in upfront and potential milestone payments, the report said.

Candid will take charge of the subsequent development of the T-cell engagers, which kill cancer cells, the filing said.